Abstract:Background: Pathological cardiac hypertrophy induced by stresses such as aging and neurohumoral activation is an independent risk factor for heart failure and is considered a target for the treatment of heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. We aimed to investigate the roles of SIRT2 in aging-related and angiotensin II (Ang II)–induced pathological cardiac hypertrophy. Methods: Male C57BL/6J wild-type and Sirt2 knockout mice were subjected to the investigation of aging-related cardiac hypertrophy. Cardiac hypertrophy was also induced by Ang II (1.3 mg/kg/d for 4 weeks) in male C57BL/6J Sirt2 knockout mice, cardiac-specific SIRT2 transgenic ( SIRT2 -Tg) mice, and their respective littermates (8 to ≈12 weeks old). Metformin (200 mg/kg/d) was used to treat wild-type and Sirt2 knockout mice infused with Ang II. Cardiac hypertrophy, fibrosis, and cardiac function were examined in these mice. Results: SIRT2 protein expression levels were downregulated in hypertrophic hearts from mice. Sirt2 knockout markedly exaggerated cardiac hypertrophy and fibrosis and decreased cardiac ejection fraction and fractional shortening in aged (24-month-old) mice and Ang II–infused mice. Conversely, cardiac-specific SIRT2 overexpression protected the hearts against Ang II–induced cardiac hypertrophy and fibrosis and rescued cardiac function. Mechanistically, SIRT2 maintained the activity of AMP-activated protein kinase (AMPK) in aged and Ang II–induced hypertrophic hearts in vivo as well as in cardiomyocytes in vitro. We identified the liver kinase B1 (LKB1), the major upstream kinase of AMPK, as the direct target of SIRT2. SIRT2 bound to LKB1 and deacetylated it at lysine 48, which promoted the phosphorylation of LKB1 and the subsequent activation of LKB1-AMPK signaling. Remarkably, the loss of SIRT2 blunted the response of AMPK to metformin treatment in mice infused with Ang II and repressed the metformin-mediated reduction of cardiac hypertrophy and protection of cardiac function. Conclusions: SIRT2 promotes AMPK activation by deacetylating the kinase LKB1. Loss of SIRT2 reduces AMPK activation, promotes aging-related and Ang II–induced cardiac hypertrophy, and blunts metformin-mediated cardioprotective effects. These findings indicate that SIRT2 will be a potential target for therapeutic interventions in aging- and stress-induced cardiac hypertrophy.

SIRT2 Acts As a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.

SIRT2 inhibition protects against cardiac hypertrophy and heart failure

Abstract 10153: SIRT1 Activation Restores Cardioprotection in the Aged Heart Against Ischemia/Reperfusion Injury

Abstract 12050: Cardiomyocyte Specific Deletion of Sirt1 Gene Alters Substrate Metabolism and Sensitizes Myocardium to Ischemia and Reperfusion Injury

Cardiomyocyte Specific Deletion of Sirt1 Gene Sensitizes Myocardium to Ischemia and Reperfusion Injury.

SIRT1 Functions As an Important Regulator of Estrogen-Mediated Cardiomyocyte Protection in Angiotensin II-Induced Heart Hypertrophy

Sirt4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.

Akt2 ablation prolongs life span and improves myocardial contractile function with adaptive cardiac remodeling: role of Sirt1-mediated autophagy regulation

SIRT2 counteracts primate cardiac aging via deacetylation of STAT3 that silences CDKN2B

Abstract 186: Impaired Nucleocytoplasmic Shuttling and Activity of SIRT1 in Response to Ischemic Stress in the Senescent Heart

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

Mouse Sirt3 Promotes Autophagy in AngII-induced Myocardial Hypertrophy Through the Deacetylation of FoxO1.

Targeting SIRT2 in Aging-Associated Fibrosis Pathophysiology

Abstract 11974: Sestrin2 Prevents Age-related Intolerance to Ischemia and Reperfusion Injury via Modulating Substrate Metabolism

SIRT3: a Potential Target for CHF?

Sestrin2 Prevents Age-Related Intolerance to Post Myocardial Infarction Via AMPK/PGC-1α Pathway.

Sirtuin 2 deficiency aggravates ageing-induced vascular remodelling in humans and mice

Cardiomyocyte Specific Deletion of Sirt1 Gene Alters Substrate Metabolism and Sensitizes Myocardium to Ischemia and Reperfusion Injury

Sirtuin 6 Protects Cardiomyocytes from Hypertrophy in Vitro Via Inhibition of NF‐κB‐dependent Transcriptional Activity

SZC-6, a Small-Molecule Activator of SIRT3, Attenuates Cardiac Hypertrophy in Mice

Mitochondrial Aldehyde Dehydrogenase 2 Accentuates Aging-Induced Cardiac Remodeling and Contractile Dysfunction: Role of AMPK, Sirt1, and Mitochondrial Function.